Literature DB >> 11598424

The inhibitory mechanism of rebamipide on the mediator release in the guinea pig lung mast cells activated with specific antigen-antibody reactions.

J Y Ro1, J Y Kim, K H Kim.   

Abstract

This study aim was to assess the effects of rebamipide on the mechanism of histamine release and biosynthesis and release of leukotrienes caused by mast cell activation. We purified mast cells from guinea pig lung tissues by the use of enzyme digestion, the rough and the discontinuous density percoll gradient method. Mast cells were sensitized with IgG1 (anti-OVA) antibody and challenged with ovalbumin. Mast cells were also stimulated with A23187 and the intracellular Ca(2+) level was measured. Histamine and leukotrienes were measured by automated fluorometric analyzer and radioimmunoassay, respectively. The intracellular Ca(2+) level was analyzed using a confocal laser scanning microscope. Protein kinase C (PKC) activity was determined by protein phosphorylated with [gamma-(32)P]ATP. The phospholipase D activity was assessed by the labeled phosphatidylalcohol. Mass 1,2-diacylglycerol (DAG) was measured by the [(3)H]DAG produced when prelabeled with [(3)H]myristic acid. PLA(2) activity was determined by measuring the arachidonic acid released from the labeled phospholipids. Rebamipide decreased the releases of histamine and leukotrienes, and completely blocked Ca(2+) influx during mast cell activation by antigen-antibody reactions. It also decreased the release of histamine and leukotrienes during mast cell activation by A23187. The PKC and PLD activities were also decreased by rebamipide in a dose-dependent manner. Rebamipide inhibited the mass DAG production and PLA(2) activity during mast cell activation. The data suggest that rebamipide inhibits intracellular signals and blocks Ca(2+) influx in mast cells activated by specific antigen-antibody reactions, which in turn inhibits histamine release and leukotriene generation. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11598424     DOI: 10.1159/000056130

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  4 in total

1.  Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution.

Authors:  Tomohisa Takagi; Yuji Naito; Kazuhiko Uchiyama; Toshimitsu Okuda; Katsura Mizushima; Takahiro Suzuki; Osamu Handa; Takeshi Ishikawa; Nobuaki Yagi; Satoshi Kokura; Hiroshi Ichikawa; Toshikazu Yoshikawa
Journal:  World J Gastroenterol       Date:  2011-09-07       Impact factor: 5.742

Review 2.  15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications.

Authors:  Tetsuo Arakawa; Kazuhide Higuchi; Yasuhiro Fujiwara; Toshio Watanabe; Kazunari Tominaga; Eiji Sasaki; Nobuhide Oshitani; Toshikazu Yoshikawa; Andrzej S Tarnawski
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

3.  Resolution of persistent corneal erosion after administration of topical rebamipide.

Authors:  Tomoyuki Kashima; Hideo Akiyama; Fumihide Miura; Shoji Kishi
Journal:  Clin Ophthalmol       Date:  2012-08-29

Review 4.  Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal.

Authors:  Tomoyuki Kashima; Hirotaka Itakura; Hideo Akiyama; Shoji Kishi
Journal:  Clin Ophthalmol       Date:  2014-05-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.